Here's the outlook on ResMed shares in 2025

Can investors breath easy?

| More on:
Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you've been paying attention to ResMed Inc (ASX: RMD) shares lately, you would know they've been on a very strong roll.

The ASX healthcare giant has enjoyed strong momentum throughout 2024, with its share price up 45% year to date.

But what does 2025 have in store for ResMed shares? Let's dive into what the experts think.

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What's driving growth in ResMed shares

ResMed's business success in 2024 is underpinned by its growing demand for obstructive sleep apnoea (OSA) products.

The company reported a 12% lift in revenue, reaching $4.7 billion for FY24, and produced $1.3 billion in free cash flow. As I've mentioned previously, that means for every dollar of revenue, 27.7 cents went straight to free cash flow.

One talking point was ResMed's myAir app, which saw patient enrolment rise by 28% year over year.

But it's not just the numbers that have investors piling into ResMed shares.

ResMed operates in a significantly underpenetrated market for OSA, of which there are an estimated 1 billion sufferers globally.

It has a dominant position in this market following the recall of Philips' competing line of continuous positive airway pressure (CPAP) machines, which are used to manage OSA.

What are analysts projecting for 2025?

Looking forward, analysts have high hopes for ResMed. According to CommSec, the consensus of analyst estimates rates it a buy.

Consensus estimates also forecast the company's earnings to grow 20% between FY25 and FY27, with a potential earnings per share (EPS) of $1.54 by the latter year.

Ord Minnett is also bullish, rating ResMed as a buy with a price target of $40.05.

The broker highlighted ResMed's strong September quarter, where revenue grew 11%, and EPS surged by 35%.

It forecasts the company to grow EPS by 13% in 2025, "which justifies its current trading multiples". ResMed trades on a price-to-earnings (P/E) ratio of 32x at the time of writing.

Meanwhile, US-based investment firm Baird also rates ResMed as a buy, citing the increasing prevalence of obstructive sleep apnoea (OSA) as a key driver.

However, it flagged concerns about potential competition from GLP-1 weight-loss drugs, which could reduce the prevalence of OSA.

Baird set a price target of US$280 for ResMed's US-listed shares, which currently sit at US$239 apiece, more than 17% upside potential.

Foolish takeout

ResMed shares are rated favourably heading into 2025. Brokers on aggregate say its a buy, and the general consensus is for reasonably strong growth next year.

In the last 12 months, Resmed is up 49%.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »